NCT04347187Recruiting
REGistry of Long-term AnTithrombotic TherApy-2
Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients With Atrial Fibrillation
Source: ClinicalTrials.gov · Last updated 1 May 2026
Brief summary (registry, in English)
To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic therapy in patients with atrial fibrillation
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2000 (estimated)
- First submitted
- 10 Apr 2020
- Start date
- Jan 2015
- Primary completion date
- Dec 2026
- Lead sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- NCT number
- NCT04347187
What you commit to
- Study type: Observational
- Planned participants: 2000
- From Jan 2015 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Subjects who are unwilling or unable to provide informed consent. ACS within 12 months before inclusion Severe CHF (NYHA IV) Stroke within 6 months before inclusion Severe liver or muscle disease Severe kidney disease / renal failure with creatinine \> 3 mg/dl Conceivable impossibility to come in touch with the patient or his family at 1-year after the intervention
Who the study is looking for
- Documented atrial fibrillation with CHA2DS2VASC \> 1
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Medical Research Center for Cardiology, Ministry of Health of Russian Federation Coordinator of this site? Confirm its status | Moscow | Russia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.